178 related articles for article (PubMed ID: 36555568)
1. Antipsychotic- and Anxiolytic-like Properties of a Multimodal Compound JJGW08 in Rodents.
Żmudzka E; Lustyk K; Głuch-Lutwin M; Mordyl B; Zakrzewska-Sito A; Mierzejewski P; Jaśkowska J; Kołaczkowski M; Sapa J; Pytka K
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555568
[TBL] [Abstract][Full Text] [Related]
2. Novel Multimodal Salicylamide Derivative with Antidepressant-like, Anxiolytic-like, Antipsychotic-like, and Anti-Amnesic Activity in Mice.
Żmudzka E; Lustyk K; Głuch-Lutwin M; Wolak M; Jaśkowska J; Kołaczkowski M; Sapa J; Pytka K
Pharmaceuticals (Basel); 2023 Jan; 16(2):. PubMed ID: 37259325
[TBL] [Abstract][Full Text] [Related]
3. Potential Anti-Amnesic Activity of a Novel Multimodal Derivative of Salicylamide, JJGW08, in Mice.
Żmudzka E; Lustyk K; Sałaciak K; Siwek A; Jaśkowska J; Kołaczkowski M; Sapa J; Pytka K
Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986498
[TBL] [Abstract][Full Text] [Related]
4. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML
J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968
[TBL] [Abstract][Full Text] [Related]
5. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.
Corbin AE; Meltzer LT; Ninteman FW; Wiley JN; Christoffersen CL; Wustrow DJ; Wise LD; Pugsley TA; Heffner TG
Neuropharmacology; 2000 Apr; 39(7):1211-21. PubMed ID: 10760363
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT.
Homan EJ; Copinga S; Unelius L; Jackson DM; Wikström HV; Grol CJ
Bioorg Med Chem; 1999 Jul; 7(7):1263-71. PubMed ID: 10465402
[TBL] [Abstract][Full Text] [Related]
7. Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.
Egashira N; Okuno R; Matsushita M; Abe M; Mishima K; Iwasaki K; Nishimura R; Oishi R; Fujiwara M
Eur J Pharmacol; 2008 Sep; 592(1-3):103-8. PubMed ID: 18644366
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
[TBL] [Abstract][Full Text] [Related]
9. New 8-aminoalkyl derivatives of purine-2,6-dione with arylalkyl, allyl or propynyl substituents in position 7, their 5-HT1A, 5-HT2A, and 5-HT7 receptor affinity and pharmacological evaluation.
Chłoń-Rzepa G; Zmudzki P; Satała G; Duszyńska B; Partyka A; Wróbel D; Jastrzębska-Więsek M; Wesołowska A; Bojarski AJ; Pawłowski M; Zajdel P
Pharmacol Rep; 2013; 65(1):15-29. PubMed ID: 23563020
[TBL] [Abstract][Full Text] [Related]
10. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.
Maeda K; Lerdrup L; Sugino H; Akazawa H; Amada N; McQuade RD; Stensbøl TB; Bundgaard C; Arnt J; Kikuchi T
J Pharmacol Exp Ther; 2014 Sep; 350(3):605-14. PubMed ID: 24947464
[TBL] [Abstract][Full Text] [Related]
11. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
12. Dopaminergic and glutamatergic models of psychosis show differential sensitivity to aripiprazole and a novel experimental compound modulating D
Vojtechova I; Tuckova K; Juza R; Stuchlik A; Kelemen E; Korabecny J; Soukup O; Petrasek T
Prog Neuropsychopharmacol Biol Psychiatry; 2023 Dec; 127():110819. PubMed ID: 37379895
[TBL] [Abstract][Full Text] [Related]
13. The antipsychotic-like effects in rodents of YQA31 involve dopamine D3 and 5-HT1A receptor.
Gou HY; Sun X; Li F; Wang ZY; Wu N; Su RB; Cong B; Li J
Pharmacol Rep; 2017 Dec; 69(6):1125-1130. PubMed ID: 29128790
[TBL] [Abstract][Full Text] [Related]
14. Cinnarizine has an atypical antipsychotic profile in animal models of psychosis.
Dall'Igna OP; Tort AB; Souza DO; Lara DR
J Psychopharmacol; 2005 Jul; 19(4):342-6. PubMed ID: 15982988
[TBL] [Abstract][Full Text] [Related]
15. New arylpiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and dihydro[1,3]oxazolo[2,3-f]purinedione targeting the serotonin 5-HT1A /5-HT2A /5-HT7 and dopamine D2 receptors.
Chłoń-Rzepa G; Zagórska A; Bucki A; Kołaczkowski M; Pawłowski M; Satała G; Bojarski AJ; Partyka A; Wesołowska A; Pękala E; Słoczyńska K
Arch Pharm (Weinheim); 2015 Apr; 348(4):242-53. PubMed ID: 25773907
[TBL] [Abstract][Full Text] [Related]
16. Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD).
Bucki A; Marcinkowska M; Śniecikowska J; Zagórska A; Jamrozik M; Pawłowski M; Głuch-Lutwin M; Siwek A; Jakubczyk M; Pytka K; Jastrzębska-Więsek M; Partyka A; Wesołowska A; Mierzejewski P; Kołaczkowski M
Eur J Med Chem; 2020 Apr; 191():112149. PubMed ID: 32105980
[TBL] [Abstract][Full Text] [Related]
17. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.
Depoortere R; Boulay D; Perrault G; Bergis O; Decobert M; Françon D; Jung M; Simiand J; Soubrié P; Scatton B
Neuropsychopharmacology; 2003 Nov; 28(11):1889-902. PubMed ID: 12902993
[TBL] [Abstract][Full Text] [Related]
18. Isoquinolinone derivatives as potent CNS multi-receptor D
Jin J; Zhang K; Dou F; Hao C; Zhang Y; Cao X; Gao L; Xiong J; Liu X; Liu BF; Zhang G; Chen Y
Eur J Med Chem; 2020 Dec; 207():112709. PubMed ID: 32877805
[TBL] [Abstract][Full Text] [Related]
19. The impact of the halogen bonding on D
Partyka A; Kurczab R; Canale V; Satała G; Marciniec K; Pasierb A; Jastrzębska-Więsek M; Pawłowski M; Wesołowska A; Bojarski AJ; Zajdel P
Bioorg Med Chem; 2017 Jul; 25(14):3638-3648. PubMed ID: 28529043
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Tada M; Shirakawa K; Matsuoka N; Mutoh S
Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
